Phase II clinical trials have demonstrated that Toripalimab combined with Axitinib as neoadjuvant therapy induces an objective response rate of 48.3%, significantly increasing tumor-infiltrating CD3+ and CD8+ T lymphocytes, suggesting that immune microenvironment reprogramming may enhance antitumor effects (5). Here, CD8A is linked to neoplasm.